In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...
A 72-year-old man with ocular hypertension presented three months after routine right phacoemulsification and toric intraocular lens (IOL) implantation with a two-week history of an irritated right eye and a sudden deterioration in right vision. His preoperative spherical equivalence was...
This study aimed to identify optical coherence tomography (OCT) biomarkers for predicting response to anti-VEGF treatment in diabetic macular oedema (DMO). Bilateral DMO patients with asymmetric response to a loading dose of anti-VEGF (ranibizumab / aflibercept) treatment were retrospectively studied....
This is a review article from two units in the UK and Australia, highlighting the supporting evidence of possible pathogenesis and treatment modalities of CMO in RP. The authors proposed that the likely mechanisms for RP-CMO involved the breakdown of...
This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...
Chronic cystoid macular oedema (CME) can develop secondary to various pathologies such as diabetic maculopathy, retinal vein occlusion and uveitis. It can cause significant visual impairment and macular damage. The therapeutic effect of corticosteroids in CME is through one or...
ODM5® is presented in a 10ml preservative free md bottle that can be used for 90 days after opening. ODM5® contains 5% sodium chloride to treat corneal oedema and 0.15% sodium hyaluronate to protect, stabilise the tear film, promote corneal...
This is a retrospective, multicentre, uncontrolled, consecutive case series from Lyon, France between April 20111 to June 2014, with minimum of one year follow-up. The clinical features including the best corrected acuity (BCVA), central subfield macular thickness (CSMT) and intraocular...
This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...
Royal College of Ophthalmologists Annual Congress 2019, Glasgow - First presented and discussed on Monday 20 May 2019, with a further presentation of results during Retina Subspecialty Day on Thursday 23 May 2019. Among patients with macular oedema secondary to...